Journal of the American Academy of Dermatology
Volume 58, Issue 4 , Pages 585-591 , April 2008

Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients

  • Noël Emile Célestin Schartz, MD, PhD

      Affiliations

    • Department of Dermatology 2, Hôpital Saint Louis AP-HP, Paris, France
    • Corresponding Author InformationReprint requests: Noël Emile Célestin Schartz, MD, PhD, Hôpital Saint Louis, Policlinique de dermatologie, 1, avenue Claude Vellefaux, F – 75475 Paris Cedex 10, France.
    • ,
  • Sylvie Chevret, MD, PhD

      Affiliations

    • Departement de Biostatistique et Informatique Médicale, U444-INSERM, Hôpital Saint Louis AP-HP, Paris, France
    • ,
  • Carolina Paz, MD

      Affiliations

    • Department of Dermatology 2, Hôpital Saint Louis AP-HP, Paris, France
    • ,
  • Delphine Kerob, MD

      Affiliations

    • Department of Dermatology 2, Hôpital Saint Louis AP-HP, Paris, France
    • ,
  • Olivier Verola, MD

      Affiliations

    • Laboratory of Pathology, ERM0220 INSERM, Hôpital Saint Louis AP-HP, Paris, France
    • ,
  • Patrice Morel, MD

      Affiliations

    • Department of Dermatology 2, Hôpital Saint Louis AP-HP, Paris, France
    • ,
  • Céleste Lebbé, MD, PhD

      Affiliations

    • Department of Dermatology 2, Hôpital Saint Louis AP-HP, Paris, France

,Accepted 2 November 2007.

References 

  1. Chang Y, Cesarman E, Pessin M, Lee F, Culpepper J, Knowles D, et al. Identification of a new human herpes virus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994;266:1865–1869
  2. Della Bella S, Nicola S, Brambilla L, Riva A, Ferrucci S, Presicce P, et al. Quantitative and functional defects of dendritic cells in classic Kaposi's sarcoma. Clin Immunol. 2006;119:317–329
  3. Pellet C, Kerob D, Dupuy A, Carmagnat MV, Mourah S, Podgorniak MP, et al. Kaposi's sarcoma-associated herpesvirus viremia is associated with the progression of classic and endemic Kaposi's sarcoma. J Invest Dermatol. 2006;126:621–627
  4. Tessari G, Naldi L, Boschiero L, Cordiano C, Piaserico S, Fortina AB, et al. Incidence and clinical predictors of Kaposi's sarcoma among 1721 Italian solid organ transplant recipients: a multicenter study. Eur J Dermatol. 2006;16:553–557
  5. Dezube BJ. Acquired immunodeficiency syndrome-related Kaposi's sarcoma: clinical features, staging, and treatment. Semin Oncol. 2000;27:424–430
  6. Fardet L, Stoebner PE, Bachelez H, Descamps V, Kerob D, Meunier L, et al. Treatment with taxanes of refractory or life-threatening Kaposi sarcoma not associated with human immunodeficiency virus infection. Cancer. 2006;106:1785–1789
  7. Cooley T, Henry D, Tonda M, Sun S, O'Connell M, Rackoff W. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma. Oncologist. 2007;12:114–123
  8. Becker G, Bottke D. Radiotherapy in the management of Kaposi's sarcoma. Onkologie. 2006;29:329–333
  9. Bodsworth NJ, Bloch M, Bower M, Donnell D, Yocum R. International Panretin Gel KS Study Group. Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma. Am J Clin Dermatol. 2001;2:77–87
  10. Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol. 2000;43(Suppl):S6–S11
  11. Fletcher S, Steffy K, Averett D. Masked oral prodrugs of toll-like receptor 7 agonists: a new approach for the treatment of infectious disease. Curr Opin Investig Drugs. 2006;7:702–708
  12. Li VW, Li WW, Talcott KE, Zhai AW. Imiquimod as an antiangiogenic agent. J Drugs Dermatol. 2005;4:708–717
  13. Beutner KR, Spruance SL, Hougham AJ, Fox TL, Owens ML, Douglas JM. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol. 1998;38:230–239
  14. Yan J, Chen SL, Wang HN, Wu TX. Meta-analysis of 5% imiquimod and 0.5% podophyllotoxin in the treatment of condylomata acuminata. Dermatology. 2006;213:218–223
  15. Hadley G, Derry S, Moore RA. Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol. 2006;126:1251–1255
  16. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50:722–733
  17. Schulze HJ, Cribier B, Requena L, Reifenberger J, Ferrándiz C, Garcia Diez A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol. 2005;152:939–947
  18. Papadavid E, Stratigos AJ, Falagas ME. Imiquimod: an immune response modifier in the treatment of precancerous skin lesions and skin cancer. Expert Opin Pharmacother. 2007;8:1743–1755
  19. Shumack S, Robinson J, Kossard S, Golitz L, Greenway H, Schroeter A, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol. 2002;138:1165–1171
  20. Rybojad M, Borradori L, Verola O, Zeller J, Puissant A, Morel P. Non-AIDS-associated Kaposi's sarcoma (classical and endemic African types): treatment with low doses of recombinant interferon-alpha. J Invest Dermatol. 1990;95(Suppl):176S–179S
  21. Costa da Cunha CS, Lebbe C, Rybojad M, Agbalika F, Ferchal F, Rabian C, et al. Long-term follow-up of non-HIV Kaposi's sarcoma treated with low-dose recombinant interferon alfa-2b. Arch Dermatol. 1996;132:285–290
  22. Tur E, Brenner S. Classic Kaposi's sarcoma: low-dose interferon alfa treatment. Dermatology. 1998;197:37–42
  23. Babel N, Elbl N, Ulrich C, Bold G, Sefrin A, Hammer MH, et al. Development of Kaposi's sarcoma under sirolimus-based immunosuppression and successful treatment with imiquimod. Transpl Infect Dis doi: 10.1111/j.1399-3062.2007.00239.x. Published online April 11, 2007
  24. Rosen T. Limited extent AIDS-related cutaneous Kaposi's sarcoma responsive to imiquimod 5% cream. Int J Dermatol. 2006;45:854–856
  25. Krown SE, Testa MA, Huang J. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS clinical trials group staging classification. AIDS clinical trials group oncology committee. J Clin Oncol. 1997;15:3085–3092
  26. Sterry W, Ruzicka T, Herrera E, Takwale A, Bichel J, Andres K, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol. 2002;147:1227–1236
  27. Duvic M, Friedman-Kien AE, Looney DJ, Miles SA, Myskowski PL, Scadden DT, et al. Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase 1 and 2 trials. Arch Dermatol. 2000;136:1461–1469

 Supported by a grant-in-aid from 3M Pharmaceuticals.

 Conflicts of interest: None declared.

PII: S0190-9622(07)02281-5

doi: 10.1016/j.jaad.2007.11.005

Journal of the American Academy of Dermatology
Volume 58, Issue 4 , Pages 585-591 , April 2008

Article Tools

* Image Usage & Resolution